Optimizing hypomethylating agents in myelodysplastic syndromes

Current Opinion in Hematology

Volumn 19, Issue 2, 2012, Pages 65-70

  Itzykson, Raphael ^a   Fenaux, Pierre ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

azacitidine; decitabine; histone deacetylase inhibitor; hypomethylating agent; myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIANEMIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZACITIDINE; BIOLOGICAL MARKER; CLOFARABINE; DNA METHYLTRANSFERASE INHIBITOR; ETANERCEPT; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; HYPOMETHYLATING AGENT; IMMUNOMODULATING AGENT; MICRORNA; NUCLEOSIDE ANALOG; PROTEIN TYROSINE KINASE INHIBITOR; RIGOSERTIB; ROMIPLOSTIM; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; BLEEDING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PRACTICE; DNA METHYLATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; GASTROINTESTINAL TOXICITY; GENE MUTATION; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OUTPATIENT CARE; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; DNA METHYLATION; DRUG ADMINISTRATION SCHEDULE; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOMODULATION; MYELODYSPLASTIC SYNDROMES; PATIENT COMPLIANCE; TREATMENT FAILURE;

EID: 84857039313     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32834ff58a     Document Type: Review

References (75)

1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higherrisk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009; 10:223-232.
2. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 2006; 106:1794-1803.
3. Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011; 29:1987-1996. Large phase III trial of DAC showing progression-free survival, but not OS improvement.
4. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20:2429-2440. (Pubitemid 34525728)
5. Tiu RV, Visconte V, Traina F, et al. Updates in cytogenetics and molecular markers in MDS. Curr Hematol Malig Rep 2011; 6:126-135.
6. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478:64-69.
7. Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010; 5:e9001. Highlights the distinct properties of AZA and DAC in vitro, stressing the need to elucidate the functional consequences of RNA incorporation of AZA.
8. Quivoron C, Couronne L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011; 20:25-38.
9. Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-Azacytidine and entinostat in patients with myeloid malignancies. Blood 2009; 114:2764-2773.
10. Thepot S, Lainey E, Cluzeau T, et al. Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. Cell Cycle 2011; 10:2323-2330.
11. Cluzeau T, Robert G, Puissant A, et al. Azacitidine-resistant SKM1 myeloid cells are defective for AZA-induced mitochondrial apoptosis and autophagy. Cell Cycle 2011; 10:2339-2343.
12. Lubbert M, Daskalakis M, Kunzmann R, et al. Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-Aza-2'-deoxycytidine (decitabine). Leuk Res 2004; 28:1267-1271. (Pubitemid 39314406)
13. Sayar H, Chan RJ, Orschell CM, et al. Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: A study of the Hoosier Oncology Group. Leuk Res 2011; 35:1108-1110.
14. Goodyear O, Agathanggelou A, Novitzky-Basso I, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010; 116:1908-1918.
15. Schmiedel BJ, Arelin V, Gruenebach F, et al. Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer 2011; 128:2911-2922.
16. Sanchez-Abarca LI, Gutierrez-Cosio S, Santamaria C, et al. Immunomodulatory effect of 5-Azacytidine (5-AzaC): Potential role in the transplantation setting. Blood 2010; 115:107-121.
17. Al Ustwani O, Francis J, Wallace PK, et al. Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells. Leuk Res 2011; 35:e35-e36.
18. Pilorge S, Doleris LM, Dreyfus F, Park S. The autoimmune manifestations associated with myelodysplastic syndrome respond to 5-Azacytidine: A report on three cases. Br J Haematol 2011; 153:664-665.
19. Qin T, Castoro R, El Ahdab S, et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One 2011; 6:e23372.
20. Fenaux P, Gattermann N, Seymour JF, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: Azacitidine compared with low dose ara-C. Br J Haematol 2010; 149:244-249.
21. Gidwani R, Khan ZM, Fenaux P, et al. A cost-effectiveness analysis of using azacitidine versus decitabine in treating patients with myelodysplastic syndromes. J Med Econ 2011. [Epub ahead of print]
22. Gurion R, Vidal L, Gafter-Gvili A, et al. 5-Azacitidine prolongs overall survival in patients with myelodysplastic syndrome: A systematic review and metaanalysis. Haematologica 2009; 95:303-310.
23. Kumar A, List AF, Hozo I, et al. Decitabine versus 5-Azacitidine for the treatment of myelodysplastic syndrome: Adjusted indirect meta-Analysis. Haematologica 2009; 95:340-342; author reply 343-344.
24. Braun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: A phase II trial. Blood 2011; 118:3824-3831.
25. Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009; 27:1850-1856.
26. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109:52-57. (Pubitemid 46053042)
27. Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009; 27:3842-3848.
28. Lee JH, Jang JH, Park J, et al. A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. Haematologica 2011; 96:1441-1447.
29. Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011; 117:2697-2702.
30. List AF, Fenaux P, Mufti GJ, et al. Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. In ASCO Annual Meeting Abstracts. 2008; abstr. 7006.
31. Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011; 117:403-411. Proposes a validated prognostic score suited for daily practice in higher-risk MDS treated with azacitidine.
32. Prebet T, Gore SD, Sun Z, et al. Prolonged administration of azacitidine with or without entinostat increases rate of hematologic normalization for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasiarelated changes: Results of the US Leukemia Intergroup Trial E1905. ASH Annual Meeting Abstracts. Blood 2010; 116:abstr. 601.
33. Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 2011; 29:2521-2527. A phase I study of oral AZA, a possible way to optimize HMA exposure.
34. Fenaux P, Bowen D, Gattermann N, et al. Practical use of azacitidine in higherrisk myelodysplastic syndromes: An expert panel opinion. Leuk Res 2010; 34:1410-1416.
35. Santini V, Fenaux P, Mufti GJ, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol 2010; 85:130-138.
36. Lee JH, Lee KH, Lee JH, et al. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome. Leuk Res 2011; 35:499-503.
37. Itzykson R, Thé pot S, Beyne-Rauzy O, et al. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine? Leuk Res 2011. [Epub ahead of print]
38. Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2011; 28:437-444.
39. Moon JH, Kim SN, Kang BW, et al. Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment. Ann Hematol 2010; 89:681-689.
40. van der Helm LH, Alhan C, Wijermans PW, et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol 2011; 155:599-606.
41. Breccia M, Loglisci G, Cannella L, et al. Application of French prognostic score to IPSS intermediate-2 or high risk myelodysplastic patients treated with 5-Azacitidine is able to evaluate overall survival and rate of response. Leuk Lymphoma 2011. [Epub ahead of print]
42. Sanna A, Cannella L, Gozzini A, et al. Comorbidities indexes in patients treated with 5-Azacitidine are an useful and easily applicable tool to refine prognostic evaluation. ASH Annual Meeting abstracts. Blood 2010; 116:abstr. 606.
43. Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010; 28:605-613. Provides a validated methylation signature by pyrosequencing that predicts outcome of patients treated with HMAs independently from routine clinical variables.
44. Blum W, Klisovic RB, Becker H, et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 2010; 28:4919-4925.
45. Follo MY, Finelli C, Mongiorgi S, et al. Reduction of phosphoinositidephospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A 2009; 106: 16811-16816.
46. Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011; 25:1147-1152. First study reporting the predictive value of a gene involved in epigenetic regulation in MDS treated with HMAs.
47. Traina F, Jankowska AM, Visconte V, et al. Impact of molecular mutations on treatment response to hypomethylating agents in MDS. ASH Annual Meeting Abstracts. Blood 2011; 118:abstr. 461.
48. Musto P, Maurillo L, Spagnoli A, et al. Azacitidine for the treatment of lower risk myelodysplastic syndromes: A retrospective study of 74 patients enrolled in an Italian named patient program. Cancer 2011; 116:1485-1494.
49. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24:3895-3903. (Pubitemid 46630737)
50. Boehrer S, Beyne-Rauzy O, Prebet T, et al. Interim results of a randomized phase II trial of azacitidine (AZA) +/-Epo in lower risk myelodysplastic syndrome (MDS) resistant to an erythropoietic stimulating agent (ESA) alone. ASH Annual Meeting Abstracts. Blood 2010; 116:abstr. 1880.
51. Grovdal M, Karimi M, Khan R, et al. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol 2010; 150:293-302.
52. Gardin C, Prebet T, Bouabdallah K, et al. A phase II study of post-remission therapy with azacitidine (AZA) in patients with AML post-MDS and high-risk MDS: A GFM Group Study. ASH Annual Meeting Abstracts. Blood 2009; 114:abstr. 844.
53. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104:579-585. (Pubitemid 38900045)
54. Koreth J, Pidala J, Perez WS, et al. A decision analysis of reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation for older patients with de-novo myelodysplastic syndrome (MDS): Early transplantation offers survival benefit in higher-risk MDS. ASH Annual Meeting Abstracts. Blood 2011; 118:abstr. 115.
55. De Padua Silva L, de Lima M, Kantarjian H, et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 2009; 43:839-843.
56. Field T, Perkins J, Huang Y, et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010; 45:255-260.
57. Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versusleukemia. Blood 2010; 116:129-139.
58. de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: A dose and schedule finding study. Cancer 2010; 116:5420-5431.
59. Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: Results of the RELAZA trial. Leukemia 2011. doi: 10.1038/leu.2011.234. [Epub ahead of print]
60. Lubbert M, Bertz H, Wasch R, et al. Efficacy of a 3-day, low-dose treatment with 5-Azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant 2010; 45:627-632.
61. Czibere A, Bruns I, Kroger N, et al. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: A retrospective analysis. Bone Marrow Transplant 2010; 45:872-876.
62. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-Aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108:3271-3279.
63. Raffoux E, Cras A, Recher C, et al. Phase 2 clinical trial of 5-Azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010; 1:34-42.
64. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-Azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007; 110:2302-2308. (Pubitemid 47523148)
65. Issa J-P, Castoro R, Ravandi-Kashani F, et al. Randomized phase II study of combined epigenetic therapy: Decitabine vs. decitabine and valproic acid in MDS and AML. ASH Annual Meeting Abstracts. Blood 2011; 112:abstr. 228.
66. Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium. J Clin Oncol 2008; 26:abstr. 7000.
67. Raza A, Mehdi M, Mumtaz M, et al. Combination of 5-Azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer 2008; 113:1596-1604.
68. Sekeres MA, List AF, Cuthbertson D, et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2011; 28:2253-2258. Pilot study of a promising combination of azacitidine and lenalidomide in intermediate or high-risk MDS.
69. Scott BL, Ramakrishnan A, Storer B, et al. Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept. Br J Haematol 2011; 148:944-947.
70. Hills RK, Burnett AK. Applicability of a 'Pick a Winner' trial design to acute myeloid leukemia. Blood 2011; 118:2389-2394.
71. Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2009; 116:3830-3834.
72. Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011; 29:3322-3327. This study, as well as [71], stresses the poor outcome of MDS patients after failure of HMAs, stressing the need for optimization of HMA therapy in the first line, and defining milestones for drug development in second line.
73. Prebet T, Braun T, Rauzy OB, et al. A phase I-II study of vorinostat and low dose cytarabine for patients treated for high risk myelodysplastic with azacytidine failure: The GFM-VOR2007 Study. ASH Annual Meeting Abstracts. Blood 2010; 116:abstr. 4003.
74. Braun T, Raffoux E, Prebet T, et al. Low-dose clofarabine has significant activity in high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia post-MDS (sAML) after azacitidine (AZA) failure: Interim results of the GFM Clo08 dose escalating phase I/II study (NCT0106325). ASH Annual Meeting Abstracts. Blood 2011; 118:abstr. 609.
75. Sekeres MA, Steensma DP. Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: Implications for clinical trial design and enrollment. Blood 2009; 114:2575-2580.